Drugs & Therapy Perspectives

, Volume 19, Issue 9, pp 4–6 | Cite as

Memantine: profile report

  • Hans Förstl
  • Anne-Sophie Rigaud
Drugs and Profile Reports
  • 18 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jarvis B, Figgitt DP. Memantine. Drugs and Aging 2003; 20(6): 465–76PubMedCrossRefGoogle Scholar
  2. 2.
    Förstl H. Memantine: a viewpoint. Drugs and Aging 2003; 20(6): 477CrossRefGoogle Scholar
  3. 3.
    Rigaud A-S. Memantine: a viewpoint. Drugs and Aging 2003; 20(6): 477–8CrossRefGoogle Scholar
  4. 4.
    Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Engl J Med 1999 Nov; 25: 341Google Scholar
  5. 5.
    Erkinjuntti T. Cerebrovascular dementia: pathophysiology, diagnosis and treatment. CNS Drugs 1999 Jul; 12: 35–48CrossRefGoogle Scholar
  6. 6.
    Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer’s disease. Int J Geriatr Psychiatry 1999; 14(1): 3–47PubMedCrossRefGoogle Scholar
  7. 7.
    Reisberg B, Doody R, Stöffler A, et al. A randomized, placebo-controlled study of memantine, an uncompetitive NMDA antagonist, in patients with moderate to severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41PubMedCrossRefGoogle Scholar
  8. 8.
    Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999 Feb; 14(2): 135–46PubMedCrossRefGoogle Scholar
  9. 9.
    Orgogozo J-M, Rigaud A-S, Stöffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002 Jul; 33(7): 1834–9PubMedCrossRefGoogle Scholar
  10. 10.
    Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002 Nov; 17(6): 297–30PubMedCrossRefGoogle Scholar
  11. 11.
    H. Lundbeck A/S. Summary of product characteristics. Ebixa (memantine hydrochloride). Valby, Denmark, 2002Google Scholar
  12. 12.
    Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine: results of a phase II double-blind study. Pharmacopsychiatry 1988 May; 21(3): 144–6PubMedCrossRefGoogle Scholar
  13. 13.
    Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 1991 Aug; 41(8): 773–80PubMedGoogle Scholar
  14. 14.
    Tempel D. Memantine in organic brain syndromes. Therapiewoche 1989; 39: 946–52Google Scholar
  15. 15.
    Pantev M, Ritter R, Gortelmeyer R. Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Z Gerontopsychol Psychiatr 1993; 6: 103–17Google Scholar
  16. 16.
    Rieke J, Glaser A. Efficacy and tolerability of memantine in patients with dementia [in German]. Med Welt 1996; 47(6): 251–4Google Scholar
  17. 17.
    Ruther E, Glaser A, Bleich S, et al. A prospective PMS study to validate the sensitivity for change of the D- scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatry 2000 May; 33(3): 103–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Hans Förstl
    • 1
  • Anne-Sophie Rigaud
    • 2
  1. 1.Department of Psychiatry and PsychotherapyTechnical University MunichMunichGermany
  2. 2.Hôpital Broca, CHU Cochin Port-RoyalUniversité René DescartesParisFrance

Personalised recommendations